Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
3 evidence topics · 3 sources
Investigational drug substance and placebo
Phase 3 doses and injection volumes
| Arm | Quoted dose and volume |
|---|---|
| Onvuzosiran every 6 months | “ADX-324 300 mg Q6M (1.5ml)” |
| Onvuzosiran every 3 months | “ADX-324 240 mg Q3M (1.2ml)” |
| Placebo matched to the 6-month regimen | “Placebo (1.5 ml) n=15” |
| Placebo matched to the 3-month regimen | “Placebo (1.2 ml) n=15” |
Material safety data sheet
No evidence found.